NEWPHARMA
ActiveSummary
NEWPHARMA has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals. The 2026 annual accounts show equity of €1.8m and a net result of -€711,789. Equity is growing by about 8.3% per year across the filed financial years. Its solvency ranks better than 15% of 346 sector peers (NACE 47, financial year 2026). The computed 12-month bankruptcy probability is 0.7% (low).
Directors
Board 4
Statutory auditor 1
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- Statutory auditor
| Name | Functions and periods |
|---|---|
| CASTELEIN, Kris Roger |
|
| GOETHAERT, Stefan Annie Willy Maria |
|
| VANDAMME, Stefaan Walter Alphons |
|
| WILLEMYNS, Jo Paul Maria Agnès Maurits |
|
| EY Réviseurs d'entreprises |
|
Owners and capital
Owners
2 ownersChain of control
- KORYS
- Colruyt Group
- Sukhino
- NEWPHARMA GROUP
- NEWPHARMA
Highest known parent: KORYS. The sources do not say who stands above it.
Owners 2
-
100%
- SMARTVALUEparent99.6%
According to the annual accounts to 31-03-2026 of NEWPHARMA and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Capital and shareholders
- 21-11-2024 Capital stated in the deed · €5,050,000 · 1,000 shares
- 17-01-2024 Converted to unavailable equity